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ABSTRACT
The regulation of heart development is an area of research that has important implications
for the future treatments of heart injuries. Cardiomyocytes, or cardiac muscle cells, stop
proliferating after birth, which limits the adult heart in its ability to repair damaged tissue
after injury. The use of targeted therapies to treat heart injury through regenerative
mechanisms requires an extremely detailed understanding of the regulatory pathways
responsible for directing proliferation of cardiomyocytes during heart development.
Interactions between cardiomyocytes in the myocardium with endothelial cells of the
endocardium during development are known to occur through cell-cell interactions,
including the action of diffusible cell signaling factors. The loss of FoxO1 expression in
endothelial cells was shown to disrupt the signaling interactions of endothelial cells and
cardiomyocytes (Sengupta et al., 2012) indicating that FoxO1 may be involved in the
regulated the signaling pathways between these two cell types. In addition, the growth
factors Neuregulin (NRG-1) and IGF-1 are known to mediate the proliferation of
cardiomyocytes during heart development (Tian & Morrisey, 2012). FoxO1 has also been
shown to regulate many signaling pathways that are involved in controlling cell
proliferation, including other growth factor pathways. The purpose of this study was to
investigate the role of FoxO1 in endothelial-cardiomyocyte interactions in an in vitro
cell co-culture model system to determine if FoxO1 has regulatory roles in
cardiomyocyte proliferation via endothelial-myocardial signaling. In this study, we
focused on the regulatory role of FoxO1 in NRG-1 expression and the effects of altered
NRG-1 expression on the interactions between endothelial cells and cardiomyocytes in
the co-culture model. We found that a lack of FoxO1 expression did affect the gene
expression of NRG-1, as well as IGF-1 and their respective receptors, ErbB2/ErbB4 and
IGF-1R. Interestingly, we also found a difference in the gene expression of our control,
depending on whether they were treated with a control siRNA scramble sequence or if
they were untreated. A clear understanding of endothelial-cardiomyocyte signaling is
essential to further development of therapeutic treatments for cardiovascular defects and
disease.
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1. INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death, not only in the
United States, but worldwide. According to data presented by the American Heart
Association from 2013, CVD results in 2200 deaths per day in the United States. CVD
was responsible for more than 17.3 million deaths per year worldwide and is estimated to
grow to more than 23.6 million by 2030 (Mozaffarian et al., 2014). Congenital birth
defects are the leading cause of deaths in infants and the most common types seen in
newborns are heart defects. Congenital heart defects occur in about 9 in every 1000 births
(Schleich et al., 2013). Diseases and congenital defects of the heart share the
characteristics of structural and functional malformations of the myocardium. Clinical
treatments of cardiovascular injury are challenging due to the complexity of the
cardiovascular system. There are several specialized cell types in the cardiovascular
system but there is one cell type in particular that plays a critical role in the development
and proper functioning of the heart, itself. Cardiomyocytes are the cells responsible for
forming the heart muscle, or myocardium, and are specified as atrial or ventricular
myocytes (Epstein, 2010). Though cardiomyocytes are just one example of the
specialized cells found in the cardiovascular system, they are particularly notable for their
role in myocardial development as a critical component of proper heart functioning, as
well as for their significant implications in diseases and defects of the heart.
In humans, cardiomyocytes proliferate throughout embryogenesis then withdraw
from the cell cycle after birth, completely losing their proliferative abilities. When
cardiomyocytes stop proliferating, growth of the myocardium stops as well. This
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cessation of growth results in the heart’s inability to repair any damaged tissue sustained
during injury, which often leads to loss of function. Importantly, loss of function in the
myocardium is associated with several types of heart disease and congenital heart defects.
Therefore, it is no wonder that studies seeking a better understanding of myocardial
proliferation and the possible regeneration of a functional myocardium receive a great
deal of attention (Xin et al., 2013).
1.1 Heart Development
The heart is the first organ to develop and begin functioning in vertebrate
embryogenesis. The developmental processes responsible for the formation of the heart
are referred to as cardiogenesis. Cardiogenesis is mediated by strict transcriptional gene
regulation and elaborate cellular signaling pathways that result in embryonic heart
formation. (Xin et al., 2013). Cardiogenesis begins about day 16 following the formation
of the three embryonic germ layers: endoderm, mesoderm and ectoderm. The heart is
formed from the anterior mesoderm, which gives rise to precardiac cells. Precardiac cells
are multipotent and have the ability to differentiate into the various cell types observed in
the mature heart. Precardiac cells also form the cardiogenic crescent, or the first heart
field. The cells of the first heart will migrate anteriorly then fuse at the midline of the
embryo, forming a linear primitive heart tube (Xin et al., 2013).
The primitive heart tube is comprised of three cardiac layers: the myocardium, the
endocardium and the epicardium. The outer layer is formed by epicardial cells, the
myocardium forms the bulk of the heart, and a layer of cardiac jelly exists between the
endocardial layer that forms the lumen of the heart. The heart tube will undergo a process
2

called looping to spatially position the future chambers of the heart. During this process,
the myocardium induces the cells of the endocardium to detach and migrate into the
cardiac jelly. These cells will migrate into the cardiac cushions to undergo differentiation
and become parts of the heart valves (Schleich, 2013). As looping continues, the
epithelial proepicardium will migrate to the myocardium’s surface. Through rapid
proliferation, proepicardial cells will cover the surface of the myocardium. These cells
will make up the epicardium and pericardium. Some epicardial cells are able to
delaminate and undergo epithelial-to-mesenchymal transitions to form mesenchymal cells.
These mesenchymal cells are able to give rise to smooth muscle , vascular endothelial
cells and fibroblasts involved in the coronary vasculature (Smith, Bader, 2007). After
looping occurs, the heart tube will undergo convergence and wedging to produce a fully
septated heart. A second population of cardiac cells, known as the second heart field, will
migrate into the pharyngeal regions of the embryo. Cells derived from the second heart
field contribute to the walls of the atria and atrial septum, muscular portions of the
systemic and pulmonary veins, the outflow tract and the muscular base of the aorta and
pulmonary arteries (Schleich, 2013).
There are three distinct developmental steps required for the proper maturation of
a four-chambered heart. The first step is the trabeculation of the myocardium, which
forms the defined trabeculae of the ventricle. Trabeculation is responsible for maintaining
embryonic blood flow during the early stages of cardiogenesis. The second step is the
formation of endocardial cushions, valves and septa. Endocardial cushions are formed
from cells of the endocardium that undergo endocardial-mesenchymal transition to

3

become mesenchymal cells. The mesenchymal cells migrate into the cardiac jelly and
push the endocardium into the cardiac lumen. The resulting protrusions give rise to the
endocardial cushions. These cushions will eventually result in the formation of the
cardiac valves and septa. The third step is myocardial compaction accompanied with
coronary vasculature formation. The outer myocardial layers become more compact
during later stages of development. During the process of compaction, this compact zone
will go from a thickness of about two myocardial cells to a multilayered wall of cardiac
cells. The compact zone will also go from being avascular to having angioblasts form
vascular tubes from the epicardium. Thickening of the myocardium is the first sign of
vascularization in the embryonic heart of vertebrates. The epicardium’s ability to undergo
epithelial-mesenchymal transition is thought to be the heart’s major source of fibroblasts,
coronary endothelium as well as vascular smooth muscle cells (VSMC). In addition, the
proepicardium, the embryonic structure giving rising to the epicardium, has proved to
have critical roles in paracrine signaling for development of the myocardium. Among
these paracrine signals, the epicardium secretes growth factors to stimulate the
myocardium to proliferate myocytes in the compact myocardial wall (Tian & Morrisey,
2012). Trabeculation, endocardial cushion formation, and myocardial compaction are all
required for proper formation of the four-chambered heart and importantly, each step
requires endocardial and myocardial signaling.
1.2 Endocardial-Myocardial Signaling
Signaling interactions between the endocardium and the myocardium have been
implicated in several critical processes in cardiogenesis. Similar to the myocardium, the
4

endocardium is derived from cardiac mesoderm, separating itself out from the linear heart
tube. The endocardium serves as an important source of mesenchymal cells for the
development of cardiac valves due to its ability to undergo endothelial-mesenchymal
transition. The endocardium has many essential roles throughout heart development,
including one of the earliest critical processes of heart trabeculation. After the cardiac
linear heart tube develops and undergoes looping to align the chambers of the heart, the
heart will undergo trabeculation which helps direct blood flow and increase contractility.
The significance of trabeculation as a result of myocardial and endocardial signaling can
be demonstrated by a specific zebrafish mutation, Cloche, which affect both endothelial
and hematopoietic lineages. Cloche mutant zebrafish lack the endocardium and many
other endothelial cells, making them a model organism to study the endocardium’s role in
trabeculation. Cloche mutants failed to develop ventricular trabeculi, which caused
reduced contractility, distended atria and collapsed ventricles (Stainer et al., 1995).
Therefore, signaling between the myocardium and endocardium is an absolute
requirement for proper formation and functioning of the heart.
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Adapted from Tian & Morrisey,
Circulation Research, 2012

Figure 1: Cell signaling between endothelial cells of the endocardium and cardiomyocytes of
the myocardium. Boxes highlight the pathways focused on in this paper.

There are several important gene networks and signaling pathways involved in the
cross-talk between endothelial cells of the endocardium and cardiomyocytes of the
myocardium (Figure 1). While some of the signaling components have been identified,
many details regarding the exact signals involved in heart development are not yet known.
Neuregulin (NRG)-1/ErbB2/B4, fibroblast growth factor (FGF)-9, -16, -29, Notch,
vascular endothelial growth factor (VEGF) and Angiopoietin-1 (Ang-1) are all known to
have essential roles in the maturation and function of myocardial cells (Smith & Bader,
2007).
Neuregulin 1 (NRG-1) has been shown to have particularly critical roles in the
development of the myocardium. Endocardial cells synthesize NRG-1 to promote
myocyte survival and proliferation by stimulating co-receptors, ErbB4 and ErbB2,
expressed on adjacent cardiomyocytes. During development, it has been shown that
NRG-1 activation of the ErbB2/ErbB4 complex is required for the process of
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trabeculation. It is also known that NRG-1/ErbB4 interactions promote differentiated
cardiomyocytes proliferation in the mature heart (Lee et al., 1995). Increased expression
of ErbB4 was shown to enhance proliferation of cardiomyocytes, while a global loss of
ErbB4 receptor caused a decrease in proliferation in cardiomyocytes. Studies have also
demonstrated the importance of NRG-1 and the ErbB2/ErbB4 complex, each as
individual components. For example, the global loss of NRG-1 in mice results in absence
of trabeculation, failure of myocardial maturation and embryonic lethality, as seen with
Cloche mutants (Lai, et al., 2010). In addition, null alleles for either the ErbB2 or ErbB4
receptors resulted in normal heart tube formation followed by normal looping but no
trabeculation.
It is important to note that NRG-1 is only able to induce proliferation in
differentiated, mononucleated cardiomyocytes, not binucleated cardiomyocytes. After
birth, cardiomyocytes become binucleated and withdraw from the cell cycle. This led to
the thought that adult cardiomyocytes are incapable of proliferating due to a specific
inability to perform cytokinesis, which is a key step in the mitotic cell cycle (Bersell et al.,
2009). The presence of NRG-1 induces the disassembly of sarcomeres to facilitate
cytokinesis, which is similar to the induction of proliferation through p38 inhibition by
FGF-1. The activation of PI3K is a common mechanism by which NRG-1, FGF-1 and a
third growth factor, Insulin-like growth factor 1 (IGF-1) are able to stimulate
cardiomyocyte proliferation. Activation of PI3K leads to the activation of PDK1 and Akt,
which promotes cell cycle entry, DNA synthesis and cytokinesis. The PI3K pathway is
also known to regulate FoxO1 transcription factor. FOXO proteins are a family within the
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Forkhead Transcription factors family. They have various kinds of roles but many are
found to control essential cellular processes including proliferation, apoptosis,
metabolism and differentiation (Wang et al., 2014). FoxO1 has also been shown to induce
expression CKIs, including p21cip1 and p27kip1, to inhibit cell proliferation (Sengupta et
al., 2013). PI3K activates AKT, which is then able to directly phosphorylate FoxO1 and
cause translocation of FoxO1 from the nucleus to the cytoplasm, thus inhibiting gene
transcription (Xin, 2013). This pathway is summarized in Figure 2.
IGF-1 has been shown to have synergistic effects with NRG-1 in the heart. IGF-1
is synthesized by endothelial cells and binds to IGF-1 receptor (IGF-1R) on
cardiomyocytes, though significant effects on cardiomyocyte development have not been
observed by IGF-1 alone (Bersell et al., 2009). When IGF-1 interacts with NRG-1, they
synergistically promote cardiomyocyte proliferation in the ventricles. These two growth
factors simultaneously increase the amount of DNA synthesis in cardiomyocytes while an
increase in the endocardial cushions and atrioventricular cushions are observed as well
(Smith & Bader, 2007).
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Figure 2: Schematic of PI3K/AKT Pathway. Growth factors like NRG-1 and IGF-1, bind to
their receptors on the cell membrane of cardiomyocytes to activate PI3K/AKT pathway, thereby
inactivating FOXO transfection factors. FOXO transcription factors, including FoxO1, regulate
the expression of target genes, such as p27kip1, p21cip and p57kip2, in turn regulating cell
proliferation and maturation.

The genomic loss of FoxO1 expression in mice (Tie2/Cre/FoxO1-/-) results in
heart malformations that lead to embryonic lethality at embryonic day 10.5 (E10.5) due
to cardiovascular failure (Figure 3). Recent studies using cell-type specific loss of FoxO1
expression have indicated that FoxO1 is required in endothelial cells for proper heart
development but it is not required in cardiomyocyte cells (Sengupta et al., 2012). Further
research must be done to determine the signaling pathways that are involved in FoxO1
regulation of cardiomyocyte proliferation.

9

Figure 3: Embryonic lethality demonstrated by knockout of FoxO1 due to cardiovascular
failure. NT: no treatment, KO: FoxO1 knock out a) Normal murine embryo at E10.5. Arrow
shows normal heart development b) Growth retardation and heart malformation (indicated by
arrow) in Tie2/Cre/FoxO1-/- KO embryo at E10.5. c) Pericardial edema (indicated by asterisk)
demonstrated in Tie2/Cre/FoxO1-/- KO embryonic lethality at E10.5. Arrow shows malformation
of heart.

1.3 Rationale
It is known that loss of FoxO1 in endothelial cells results in extreme
morphological defects in embryos, growth retardation in overall embryonic development,
heart failure and embryonic lethality by E11. FoxO1 mutant embryos also lack
trabeculation of myocardium, have hypoplastic endocardial cushion formation and a very
thin compact layer of myocardium. However, in contrast, specific loss of FoxO1 in
cardiomyocytes does not have any phenotypic effects on myocardial development
(Sengupta et al., 2012). Therefore, it can be concluded that FoxO1 is required in
endothelial cells for normal endocardial signaling to adjacent cardiomyocytes to maintain
proper cardiovascular function but FoxO1 is not required by cardiomyocytes. It is
thought that growth factors including NRG-1 and IGF-1 may have roles in activating the
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PI3K/AKT signaling pathway, which is thought to deactivate FoxO1 by inducing
translocation from the nucleus to the cytoplasm. However, the exact signaling pathways
that result in the cardiovascular defects observed in endothelial-specific loss of FoxO1
are not yet known.
In my project, I aimed to further investigate the role of FoxO1 during
cardiovascular development by observing the effects of loss of FoxO1 expression on the
signaling interactions between cardiomyocytes and endothelial cells. Though it is known
that FoxO1 in endothelial cells is required for proper signaling, though the specific
mechanism responsible for these interactions are not known. The purpose of this study
was to investigate the role of FoxO1 in endothelial-cardiomyocyte interactions in an
in vitro cell co-culture model system to determine if FoxO1 has regulatory roles in
cardiomyocyte proliferation via endothelial-myocardial signaling. I used siRNA
(small interfering RNA) for a cell type-specific silencing of FoxO1 expression in
endothelial cells to study the implications that endothelial-specific loss of FoxO1 has on
cardiomyocyte-endothelial cell signaling. Transfection of FoxO1 siRNA allowed for the
cell-type specific removal of FoxO1 expression in an in vitro model system, similar to the
in vivo study conducted in the paper ‘FoxO1 is required in endothelial but not
myocardial cell lineages during cardiovascular development’, with the use of Tie2Cre
transgenic mice (Sengupta et al., 2012).
I also investigated the signaling of NRG-1 between cardiomyocytes and
endothelial cells to determine if cardiomyocyte proliferation and heart development could
possibly be mediated through the PI3K/AKT signaling pathway. Recent studies have also
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shown that NRG-1 has the ability to promote cardiac regeneration after ischemic injury
by inducing proliferation via ErbB4 receptor stimulation. Therefore, NRG-1 and its
ErbB4 receptors may be potential targets for therapeutic techniques to repair heart
damage following cardiac injury (Tian & Morrisey, 2012). I investigated the gene
expression of IGF-1 and its receptor IGF-1R, since studies have indicated that IGF-1
works synergistically with NRG-1 in heart development (Evans-Anderson, et al., 2008).
There is a tremendous amount of clinical significance in studying the interactions
between endothelial cells and cardiomyocytes. Cardiovascular disease and congenital
heart defects have extensive effects across the United States and communities around the
world. Cell-based regenerative approaches in therapeutic techniques point to promising
new clinical treatments of cardiac injury (Alexander & Bruneau, 2010). These therapies
aim to transplant stem cells into injured hearts to repair the cardiac tissue damage
associated with heart disease or congenital heart defects with new, functional cardiac
cells. Therefore, the key to discovering therapeutic methods of regenerating the heart is
through a deeper understanding of the specific cell signaling that occurs between the
myocardium and the endocardium during heart development.
1.4 Specific Aims
1. To develop a co-culture model system using cardiomyocytes and endothelial cells,
creating an in vitro environment that emulates the conditions of early
cardiovascular development in vivo.
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I developed a co-culture model of cardiomyocytes and endothelial cells to study
the cell signaling interactions that occur between the two cell types (Figure 4). Coculture model systems create a 3D cellular environment for the cultures to grow and
interact with their surroundings. 2D cell culture models are inadequate when compared to
3D culture models in the way they allow cells to attach, grow, affect their morphology
and overall function. By using a 3D culture model via Transwell inserts, the
cardiomyocytes and the endothelial cells were able to communicate in similar ways as
they would in vivo. The Transwell insert provide permeable support for the cell cultures
and allow for the analysis of the individual cell types, the cell matrix media and the cell
lysates that accumulated over the duration of the co-culture (Sanyal, 2014).

Katrina Harmon, 2013

Figure 4: Cardiomyocyte and Endothelial Cell Co-Culture Schematic.
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2. To examine the activity of growth factor Neuregulin in co-cultures that
contain control endothelial cells and cardiomyocytes in comparison to the cocultures that contain treated endothelial cells that lack FoxO1 expression.
I analyzed the expression of NRG-1 in endothelial cells and ErbB2/ErbB4
receptors in cardiomyocyte cells in both co-cultures containing treated endothelial cells
with silenced FoxO1 expression as well as control endothelial cells with normal FoxO1
expression. Quantitative analysis of the various gene expression levels was performed by
real time Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR). I also analyzed
the gene expression of IGF-1 and IGF-1 receptor. Altogether, the aim of this analysis was
to determine whether FoxO1 expression affects NRG-1 signaling during heart
development. I hypothesized that there would be a decrease in the level of NRG-1
expression between cardiomyocytes and endothelial cells in co-cultures with endothelial
cells that lack FoxO1 expression compared to co-cultures with control endothelial cells,
thus resulting in decreased cardiac myocyte proliferation.
Identification of the effects of FoxO1 expression on cell signaling between
endothelial cells and cardiomyocytes would disclose important information about the
detailed processes that occur during heart development. Furthermore, the elucidation of
specific signaling events involved in the regulation of cardiomyocyte proliferation is
necessary to further investigate the induction of cardiomyocyte proliferation in the adult
heart as a possible regenerative mechanism in the treatment of heart injury.
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2. METHODS
2.1 Cell Culture
HL-1 Cell Line
HL-1 murine cardiomyocyte cell line was previously obtained from Dr. William
C. Claycomb’s Laboratory at Louisiana State University. A special preparation of growth
media is required for the HL-1 cells: Claycomb medium, which was obtained from JRH
Biosciences and the bottle must be wrapped in aluminum foil due to its light sensitivity.
The media will be supplemented with 10 mL of Fetal bovine serum (FBS), 1 mL of
penicillin (100 U/mL), 1 mL of streptomycin (100 µg/mL), 1 mL of Norepinephrine
(10mM stock) and 1 mL of L-Glutamine (200 mM stock). I will be following all of the
HL-1 Specific Procedures on Cell Culturing, Passage, Freezing and Thawing provided by
Dr. Claycomb’s Laboratory. See Appendix 1 for detailed description of the procedures
(Claycomb, not dated).
C166 Cell Line
C166 murine endothelial cell line was previously purchased from ATCC (#CRL2581). I followed the cell culturing protocol provided by Dr. Evans-Anderson as well as
the guidelines provided by ATCC upon purchase, both of which can be found in
Appendix 2. According to these procedures, the following materials are required for
proper C166 cell culturing and were purchased from ATCC: one bottle Trypsin-EDTA
solution 1X, five bottles of Dulbecco’s Phosphate Buffered Saline (D-PBS), one bottle
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Fetal Bovine Serum, five bottles of Dulbecco’s Modified Eagle’s Medium (DMEM) and
1 bottle of Dimethylsulfoxide (DMSO).
C166 cells and HL-1 cells were cultured individually to increase the population of
each cell type. Cell cultures were grown to confluence and then split until we obtained a
sufficient amount of cells to implant into each co-culture model.
2.2 Co-Cultures Models
Polyethylene Transwell-Clear 0.4 µm pore size inserts (Corning; catalog# 3450)
were used to construct the 3D cell culture model. HL-1 cells were placed on the bottom
of the culture model, on the 6-well plate surface. The C166 cells were suspended in the
wells, on the surface of the inserts. This cell culture set up enables cell-cell
communication between the HL-1 and C166 cells, while allowing the separation of the
two cell lines for analysis. The cells were placed into the co-culture model following
C166 siRNA transfection, which is explained in the following section.
Insert Pore Size Optimization
Optimal Transwell insert pore size was determined by culturing C166 cells on
0.4 µL pore size inserts and 3 µL pore size inserts, then comparing cell growth between
the two sizes. Inserts were also removed to evaluate if cells were able to move past the
insert and into the bottom of the 6-well plate.
Cell Culture Media Optimization
Cell media optimization experiments were performed to evaluate the response of
HL-1 cells and C166 cells when exposed to Supplemented DMEM and Supplemented
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Claycomb Media, respectively. Cell growth was evaluated at different media volumes
for the HL-1 and C166 co-culture design. Based on Transwell’s recommended volumes
for the 6-well plates as well as the inserts, 1 mL, 1.5 mL and 2 mL of media were added
to three different wells containing HL-1 cells on 6-well plate and C166 cells on the
inserts. After 24-48 hours, inserts were placed into empty wells to evaluate the growth of
both cell types individually.
Cell Volume Optimization
Cell growth was evaluated at different cell volumes for both HL-1 and C166 cells.
Based on Transwell’s recommended volumes for the 6-well plates as well as the inserts,
250 µL, 500 µL and 1 mL volumes of HL-1 cells were added to the 6-well plate, as well
as C166 cells to the inserts. After 24-48 hours, the inserts were placed into empty wells to
evaluate the growth of both cell types individually.
2.3 siRNA silencing of FoxO1 Expression
SignalSilence FoxO1 siRNA II from Cell Signaling was used to reduce or remove
FoxO1 signaling from the endothelial cells. This allowed for the observation of changes
in cell-cell communication between cardiomyocytes and endothelial cells, depending on
endothelial cell treatment. The first control group of endothelial cells that did not undergo
transfection at all (E4-NTC). The second control group of endothelial cells did undergo
transfection but received a control scramble siRNA that did not induce a change in
FoxO1 expression (E3-SiC). Two treatment groups of endothelial cells were transfected
and received the FoxO1 siRNA to reduce or remove the proteins expression (E1-SiF and
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E2-SiF). 100nM of FoxO1 siRNA was used to transfect the endothelial cells using
Lipofectamine 2000 from Invitrogen. The cardiomyocytes did not receive any
transfection. The three experimental groups were then cultured under normal cell
culturing conditions for 24 hours post-transfection before they were transferred to the coculture model, where all cells were treated with Claycomb media and incubated for 48
hours. Detailed transfection procedures were provided by Dr. Evans-Anderson and can be
found in the Appendix 2.
Sample
Abbreviations
E1-SiFx

Endothelial

FoxO1 siRNA to silence FoxO1 gene expression; Group 1

E2-SiFx

Endothelial

FoxO1 siRNA to silence FoxO1 gene expression; Group 2

E3-SiC

Endothelial

SiRNA Control

E4-NT

Endothelial

No Treatment Control

C1+E1-SiFx

Cardiomyocyte

Co-cultured with Group 1 Endothelial cell + FoxO1 siRNA

C2+E2-SiFx

Cardiomyocyte

Co-cultured with Group 2 Endothelial cell + FoxO1 siRNA

C3+E3-SiC

Cardiomyocyte

Co-cultured with Endothelial cell + Control siRNA

Cell Type

Treatment

C4+E4-NT
Cardiomyocyte
Co-cultured with Endothelial cells with No Treatment
Table 1: Experimental Group Identification. Details for the experimental groups, indicating
sample abbreviation, cell type and specific treatment.

2.4 Western Blot Analysis
Western Blot Analysis is used to detect the presence of a specific protein in a
sample by using gel electrophoresis to separate proteins based on their 3D structures and
size (Lenico Technologies). This process is done by using primary antibodies to bind to a
target protein, followed by the binding of a secondary antibody, which is conjugated with
peroxidase. When the secondary antibody is exposed to the substrate contained in the
ECL reagents, the conjugated peroxidase cleaves the substrate to emit light. This light is
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detected by the blot reader and creates an image seen in Figure 6, with bands indicating
presence of target genes.
Western blot analysis was used to confirm that FoxO1 expression had been
reduced or removed following siRNA transfection into endothelial cells. Lanes 2-4
contained cell samples isolated 24 hours post-transfection, while Lanes 5-7 contained cell
samples isolated 48 hours post-transfection. FoxO1 primary antibody was purchased
from Cell Signaling (Product Number-C29H4) to bind to any FoxO1 proteins that was
present in the sample. A 1:1000 dilution was prepared for FoxO1 primary antibody in 1%
milk/TBS , as the manufacturer’s suggested dilution range was 1:1000 to 1:50,000
dilution range from a 1 mg/mL stock. Anti-Rabbit HRP conjugated secondary antibody
was purchased from Santa Cruz Biotechnology. A 1:10000 dilution was prepared for the
secondary antibody in 1% milk/TBS, as the manufacturer’s suggested dilution range was
1:50,000 to 1:250,000 from a 1 mg/mL stock. PierceTM Enhanced Chemiluminence
(ECL) Western Blotting substrate from ThermoFischer was used for protein detection,
followed by blot imaging using the Bio-Rad’s Gel-Doc EZ imaging system. The detailed
Western Blot Analysis protocol followed in this study was provided by Dr. Glasscock
and can be found in Appendix 3.
2.5 RNA Isolation and Conversion
The HL-1 and C166 cells were co-cultured together for 48 hours before they were
removed for analysis. Treatment groups were pooled together from the three plates,
respectively. RNA was isolated using Trizol RNA purification kit from Invitrogen.
Thermo Fischer’s NanoDrop2000 spectrophotometer was used to determine the
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concentration of RNA present in each sample (in ng/µL), which not only confirms
whether the RNA isolation was successful but it also provides dilution information
required for the conversion of RNA to cDNA. Quality of RNA can also be determined by
comparing the 260/280 absorbance ratios, which indicates the amount of ‘pure’ RNA.
The optimal 260/280 ratio is 2.0 for RNA. A second measurement for RNA quality is
determined by comparing the 230/260 absorbance ratios, which indicates how much of
the sample is purely nucleic acid. The optimal 230/260 ratio is also around 2.0.
RNA was converted to cDNA using iScriptTM cDNA Synthesis Kit from Bio-Rad,
following manufacturers protocol, then stored at -20°C until RT-PCR analysis.

Table 2: RNA Isolation Spectrophotometry. Data collected from spectrophotometer from
RNA isolated from each sample, indicating RNA concentration, 260/280 and 260/230 ratios
(2.0 is ideal for 260/280 and 260/230 ratios)

2.6 RT-PCR Analysis
cDNA samples were combined with SsoUniversal Advanced SYBR Green
Supermix, Reverse Transcriptase and nuclease-free water in preparation for RT-PCR
analysis according to Bio-Rad’s protocol for customized PrimePCR Plates (Figure 5).
Samples were loaded in triplicate for each gene assay. PrimePCR plates were run using
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the CFX96 Touch Real-Time PCR Detection System. Data was analyzed and exported
from CFX Manager Software.

Figure 5: PrimePCR Plate Design. Plates contained 5 unique gene assays, 1 reference gene
and controls, including: PCR, Reverse transcriptase, RNA Quality; Empty: positive and
negative controls
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3. RESULTS
3.1 Co-Culture Optimization
Optimization experiments were performed to determine optimal pore size for the
Transwell culture plates by comparing C166 cell growth on 0.4 µm and 3 µm insert pore
sizes. The insert pore size of 0.4 µm showed superior C166 cell growth compared to the 3
µm pore size. The 3 µm pores appeared to be too large to cultivate sufficient C166 cell
growth, due to the reduced number of endothelial cells present on the 3 µm insert when
compared to the 0.4 µm insert. In addition, C166 cells were found on the bottom of the 6well plate, which indicated that the 3 µm pores were large enough to allow C166 cells to
pass through, which defeats the purpose of our co-culture design.
Optimization experiments were performed to observe both HL-1 and C166 cells
in response to DMEM media and Claycomb media, respectively. Resulting cell growth
indicated that Claycomb media supported the growth of both HL-1 and C166 cells.
Interestingly, I observed increased growth of C166 in Claycomb media when compared
to DMEM media, which is normally used in C166 cell culture. The increased C166
growth could be attributed to the increased amount concentration of growth factors like
epinephrine and FBS contained in supplemented Claycomb media as compared to
supplemented DMEM.
Following cell media optimization, optimal cell and media volume were
determined for the co-culture system to support both HL-1 and C166 cell growth. I found
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the optimal cell volume to be 0.5 mL of cells and the optimal media volume to be 1 mL
of media, based on cell growth comparisons for each cell type in varying conditions.
3.2 Western Blot Analysis

80 kDa
60 kDa

Figure 6: Western Blot Analysis of FoxO1 Expression in C166 Endothelial cells. White
arrows show the bands at approximately 78 kDa, indicating presence of FoxO1 expression.

As shown in Figure 6, western blot analysis showed loss of FoxO1 protein from
endothelial cell cultures. Lanes containing samples from non-transfected endothelial
cells (E-NT) showed a band near 80 kDa in 24 hour-post-transfection time point samples,
which indicates normal FoxO1 expression. Endothelial cells treated with SignalSilence
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for FoxO1 (E-SiFx) or the scrambled sequence (E-SiC) did not have bands in samples
taken 24 hours post transfection, which indicates loss of FoxO1 protein. However, there
was a band in E-SiC samples in 48 hour-post-transfection time point samples, which
indicates FoxO1 expression. There was not a band in E-SiFx samples in 48 hour post
transfection samples, which indicates loss of FoxO1 protein. Thus, 48 hours post
transfection was previously determined as the optimal time point to determine reduced or
removed gene expression of FoxO1 following siRNA transfection of C166 cells. The
absence of bands at approximately 78 kDa in Lane 6 (E-SiFx) indicates FoxO1
expression was silenced and that transfection was successful.
3.3 RNA Isolation
I used spectrophotometry following the RNA isolation to determine the
concentration of RNA in each sample, as well as the quality of the RNA by comparing
260/280 and 230/260 absorbance ratios. With the exception of E1-SiFx, there was a
significant amount of RNA isolated from each endothelial samples. The 260/280 ratios in
the endothelial samples were all very close to 2.0, which indicates high quality of isolated
RNA. The 230/280 ratios in the endothelial samples were not very close to the 2.0 ratio,
ranging from 1.19 to 1.74 (Table 1), which indicates ethanol contamination. The
cardiomyocyte samples had considerably lower concentrations of RNA compared to the
endothelial samples. The 260/280 ratio in the cardiomyocyte samples were relatively
close to 2.0, but not as close as the endothelial samples. However, the 230/260 ratios in
the cardiomyocytes were not close to 2.0 and varied greatly from one another, indicating
a low quality of pure nucleic acid in these samples (Table 2). Residual ethanol that was
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not completely removed during RNA isolation is a possible explanation for the poor
230/260 ratios measured in the cardiomyocyte samples and the slightly decreased
230/260 ratios measured in the endothelial samples.
3.4 RT-PCR Analysis

Figure 7: PCR Amplification Curve for Cardiomyocyte samples. RFU: Relative
fluorescence units. Green line represents threshold for determining relative gene expression.

Real time RT-PCR was conducted using the PrimePCR plates. The results of the
amplification curves can be seen in Figure 7. Using the BioRad CFX analysis software,
relative normalized gene expression values were reported for NRG-1, ErbB2, ErbB4,
IGF-1 and IGF-1 in all samples. All triplicate values were averaged for each respective
sample. I transformed the average relative normalized gene expression values for each
sample into fold-change differences by normalizing the treatment groups with a control
group. Since there were two control groups for each cell type (siRNA controls- E3-SiC
and C3+E3-SiC and no treatment control- E4-NT and C4+E4-NT), I calculated two sets
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fold-change values:
1) Fold-change differences observed in treatment groups when normalized against
siRNA control groups, E3-SiC and C3+E3-SiC (Table 4),
2) Fold-change differences observed in treatment groups when normalized against
no treatment control groups, E4-NT and C4+E4-NT (Table 5).
Fold-change differences were graphed to represent gene expression changes in treatment
samples in Figure 8 and Figure 9 (corresponding to Table 3 and Table 4, respectively.)

Table 3: Fold-Change Differences for Treatments. Fold-change differences observed in
treatment samples normalized by their respective siRNA control groups (E3-SiC or C3+E3-SiC).
Green: up-regulated fold-change. Red: down-regulated fold-change.

Table 4: Fold-Change Differences normalized by E4-NT. Fold-change differences observed in
treatment samples normalized by their respective no treatment control groups (E4-NT or C4+E4NT). Green: up-regulated fold-change. Red: down-regulated fold-change.
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Figure 8: Gene expression of treatment samples when normalized by E3-SiC. Gene
expression difference in treatment samples by fold-change difference when normalized by their
respective siRNA control groups (E3-SiC or C3+E3-SiC). Based on the data given in Table 3.
Negative values indicate down-regulated.

Figure 9: Gene expression of treatment samples when normalized by E4-NT. Gene
expression difference in treatment samples represented by fold-change difference when
normalized by their respective no treatment control groups (E4-NT or C4+E4-NT). Based on
the data in Table 4. Negative values indicate down-regulation.
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Figure 10: Magnified view of the E4-NT normalized gene expression. Fold change difference
in treatment samples when normalized by no treatment control groups (E4-NT or C4+E4-NT) as
seen in Figure 10, graphed on using a smaller scale on the horizontal axis. ErbB4**: upper range
of fold change differences in E1-SiFx (135.27) and E2-SiFx (69.68) not shown on graph.

The expression levels of the treatment groups that were normalized against the no
treatment control (E4-NT and C4+E4-NT) expression levels had significantly larger foldchanges when compared to the treatment groups normalized with the siRNA control
groups (Figure 8 v. Figure 9 and Figure 10). Specifically, the ErbB2 and ErbB4
expression fold-changes observed in both E1-SiFx and E2-SiFx groups (normalized
against E4-NT) each had a significantly higher magnitude than any other expression level
fold-change observed. Because of these large fold-change values, the axis scale in Figure
9 makes it difficult to accurately interpret changes in expression levels for the other genes
measured, especially those with much smaller fold-change values. Therefore, I graphed
the same fold-change data displayed in Figure 9 (also found in Table 4) using a smaller
scale on the horizontal axis to magnify the smaller changes in expression levels observed
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in NRG-1, ErbB2, IGF-1 and IGF-1R (Figure 10). For endothelial cells, gene expression
levels were down-regulated in both samples when normalized against E3-SiC, except
ErbB4 and IGF-1R in E1-SiFx, which had 1.62 and 1.05 fold-change differences,
respectively. Interestingly, almost all of the gene expression levels were up-regulated in
both samples when normalized against E4-NT, except IGF-1R in E2-SiFx, with a foldchange difference of 1.54 (negative; down-regulated).
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4. DISCUSSION
In this project, I developed a co-culture model system to study NRG-1 and IGF-1
signaling from endothelial cells to ErbB2/ErbB4 and IGF-1R on cardiomyocytes to
emulate signaling events that occur during heart development. As seen in Figure 2,
NRG-1 and IGF-1 are both able to activate the PI3K/AKT pathway, which is able to
directly phosphorylate FoxO1 to induce translocation from the nucleus to the cytoplasm,
therefore, making it inactive for transcription of its target genes. Its target genes including
cyclin kinase inhibitor, cause cells to withdraw from the cell cycle, leading to the
cessation of cell proliferation. When FoxO1 expression is completely silenced in murine
embryo, there are extreme malformations of the heart leading to embryonic lethality.
Importantly, the phenotype associated with the FoxO1-/- embryo shows an absence of
trabeculation in the ventricles, endocardial cushion formation and proper myocardial
compaction, indicating that endocardial signaling is affected by the global loss of FoxO1
expression.
The co-culture design used in this project (Figure 4) provided an in vitro
representation of signaling interactions between endothelial cells of the endocardium and
cardiomyocytes of the myocardium that occur in vivo. In vitro cell culture systems cannot
completely replicate in vivo processes; however, a co-culture model system allows for
individual treatments as well as a more direct analysis of cells. By culturing the
cardiomyocytes on 6-well plates and culturing endothelial cells on the 0.4 µm Transwell
co-culture inserts, I used SignalSilence siRNA to reduce or remove FoxO1 expression,
thereby ‘silencing’ it’s function in the endothelial cells. I hypothesized that there would
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be a decrease in expression for NRG-1, IGF-1 and their receptors, ErbB2, ErbB4 and
IGF-1R when FoxO1 expression was silenced.
4.1 Gene expression
Control Samples: SiC v. NT
The gene expression of NRG-1, ErbB2, ErbB4, IGF-1 and IGF-1R each cell
sample (8 total; 4 cardiomyocyte samples and 4 endothelial samples). Surprisingly, when
I compared the expression levels of corresponding genes in the siRNA control samples vs.
the no treatment control samples for both cell types, I observed extreme differences in
expression level fold-changes. Ideally, gene expression would be the same in both types
of control samples, since the control siRNA contains a scramble sequence, which does
not have any function once transfected into the cell. Because of how substantial the foldchange differences were for the siRNA controls v. the NT controls expression level, I
created two sets of normalized fold-change values for each cell type, as seen in Table 4
and Table 5. These results could indicate that the process of siRNA transfection into
endothelial cells affected gene expression levels. Transfection is a stressful process for
cells so it is not unreasonable to think that the siRNA treatment affected expression level
by a considerable amount when compared to the no treatment controls. Because of this
information, I normalized all of treatment sample expression levels against both the
siRNA control and the no treatment control expression levels (Table 3 and Table 4). In
this study, the fold-changes in expression normalized against the siRNA controls support
the hypothesis while expression changes normalized against the no treatment controls did
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not. Further experiments would be needed to draw conclusions regarding these
differences.
In the endothelial treatment samples, fold-change differences in gene expression
levels of E1-SiFx and E2-SiFx normalized by E3-SiC showed down-regulation of
expression of NRG-1, ErbB2 and IGF-1. IFG-1R and ErbB4 were up-regulated only in
the E2-SiFx sample, but it is difficult to make conclusions with such limited data.
In the cardiomyocyte treatment samples, fold-change differences in gene
expression levels of C1+E1-SiFx and C2+E2-SiFx normalized by C3+E3-SiC both
showed down-regulation of expression of NRG-1, ErbB2 and IGF-1, similar to the
endothelial cell samples. IGF-1R was up-regulated in C1+E1-SiFx but down-regulated in
C2+E2-SiFx. No expression levels were detected for ErbB4 in either C1+E1-SiFx and
C2+E2-SiFx samples. Again, additional data from repeated trials would have helped
interpret the data from a biological point of view. Quality of RNA (Table 2) could have
affected the detection of ErbB4. Taken together, the data supports the hypothesis that
there is a decrease in NRG-1 and IGF-1 expression when FoxO1 expression is absent.
4.2 Limitations
Due to personnel changes in Dr. William Claycomb’s lab, I was unable to obtain
any more HL-1 cells during my research. This left our lab with a limited amount of HL-1
cells stored in cryopreservation. The HL-1 cells became contaminated mid-way through
my research therefore I was forced to pull from our limited quantity of frozen cells. The
HL-1 cells we had in cryopreservation were of a very high passage, with some dating
back to the early 2000’s; however, these cells were my only option for cell culture at that
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point in my research. Cryopreservation is an extremely stressful process for cells to
undergo and thousands of cells are killed in the process. In addition, cell lines decrease in
stability as well as integrity as their age and passage number increase. Therefore, the
chances of successfully culturing the HL-1 cells left in cryopreservation were very slim.
Multiple trials of the co-cultures would have been ideal but unfortunately, I was not able
to culture the amount of HL-1 cells necessary carry out more than one trial. That being
said, the experimental trial I was able to complete was done in triplicate and produced a
sufficient amount of RNA and DNA for a significant analysis. In addition, because I was
only able to perform one experimental trial, I could not use statistical analysis to compare
multiple data sets as I would have preferred.
4.3 Future Directions
I would first recommend future studies complete additional trials of this coculture system to collect a substantial amount of data to perform statistical analysis. I
would also recommend studies investigating the differences in siRNA expression levels
compared to no treatment controls, given the significant differences observed in the
results of this project.
The immortalized HL-1 cardiomyocyte cell line provides a convenient way to
study heart development in a cell culture environment, in addition to serving as a simpler
alternative to using primary cardiomyocyte cells. In order to study cardiomyocyte
proliferation, the cells must be isolated from an embryo of timed-pregnant mice, which is
a more time-consuming and costly way to study cardiomyocyte cell cultures. However,
recent advances in stem cell biology and culturing methods have made the use of HL-1
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cardiomyocytes a less popular choice in cell culture labs. The use of multipotent stem
cells derived from human somatic cells has become extremely popular in cell culture
research. Specifically, the ability to induce these derived mesenchymal stem cells into
various different cell types has created many new opportunities for cell culture research.
For example, human adipose-derived stem cells (ADSCs) can be induced to differentiate
into cardiomyocyte cells. Cell cultures using this method of induced differentiation to
cardiomyocytes is a much more attractive option than using the immortalized HL-1 cell
line. For future cell culture studies in heart development, I would recommend the use of a
co-culture model system between cardiomyocytes and endothelial cells to emulate early
in vivo cellular signaling involved in cardiomyocyte proliferation and heart development.
I would also recommend the method of induced differentiation of human ADSC to
produce human cardiomyocytes.
4.4 Conclusions
Though my thesis project was limited by my ability to acquire more
cardiomyocyte cells, my execution of the cardiomyocyte-endothelial cell co-culture
system proved to be a promising technique in studying early cell signaling events that
occur during heart development in vivo. The successful endothelial-specific FoxO1 knock
down allowed me to study the affect of FoxO1 gene expression on the expression of
genes known to have significant roles in heart development. In addition, the co-culture
design allowed me to further investigate the affect of gene expression levels on in vitro
cell-cell signaling interactions between cardiomyocytes and endothelial cells to emulate
signaling between the myocardium and endocardium in vivo. My results provide further
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support that FoxO1 expression could be regulated by the PI3K/Akt pathway, which is
activated by growth factors like NRG-1 and IGF-1. It is my hope that my project might
assist in the pursuit of a deeper understanding of myocardial-endocardial signaling in the
developing heart, as these signals remain key to discovering therapeutic methods for
heart regeneration.
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APPENDIX 1
HL-1 Cell Culture Procedures
Provided by Dr. William Claycomb
I. HL-1 Media Solutions
Complete Claycomb Medium
50 mL
100 mL
200 mL 500 mL
FBS
5 mL
10 mL
20 mL
50 mL
Pen/Strep
0.5 mL
1 mL
2 mL
5 mL
Norepi
0.5 mL
1 mL
2 mL
5 mL
(10mM)
L-Glut
0.5 mL
1 mL
2 mL
5 mL
(200mM)
Claycomb 43.5 mL
87 mL
174 mL
435 mL
Wrap in aluminum foil, since the medium is extremely light sensitive.
• Supplemented media is good for two weeks;
o At 2 weeks, can replenish the L-glutamine once
Norepinephrine (mw 319.3): 10 mM Stock in 30 mM Ascorbic Acid
1. Add 0.148 g ascorbic acid to 25 ml of cell culture grade distilled water.
2. Add 80 mg norepinephrine to the 25 ml of 30 mM ascorbic acid.
3. Filter-sterilize using 0.2 µm Acrodisc syringe filter
4. Aliquot in 1 ml volumes into sterile freezer vials with screw caps, and store at -20C. This is
10mM (stock) norepinephrine. Use 1 mL of stock per 100 mL medium for a 0.1 mM final
concentration.
• Good for one month in -4 C freezer
Gelatin/Fibronectin
1. Prepare 200 ml of 0.02% gelatin – 0.04 g in 200 ml dH2O.
2. Autoclave and allow to cool to room temperature.
3. Add 1 ml fibronectin solution, mix.
4. Aliquot 12 ml volumes in 15 ml conical tubes and freeze. This can be refrozen after
thawing.
L-Glutamine
• Comes as 100x solution
• Aliquot 12 mL volumes into 15 mL conical tubes
Claycomb Wash Medium
Media 95 mL
FBS 5 mL
Freezing Medium
FBS
9.5 mL
DMSO 0.5 mL
• This can be stored up to a week at 4°C.
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II. HL-1 Cell Culturing
A. Coating Plates
1. Coat plate with gel/fibro and incubate for at least an hour before culture
a. 1 mL/well for 6-well
or 3 mL for 100 mm/T75
2. Remove the gelatin/fibronectin and wash plate with Claycomb Wash
3. Add new media then place back in incubator until ready to add cells
a. 1 mL for 6-well
b. 5 mL for 100 mL
c. 10 mL for T75
B. Thawing
1. Gelatin/fibronectin coat a plate for at least an hour in the incubator
2. Remove the gelatin/fibronectin from the flask and replace with 10 mL of supplemented
Claycomb medium. Place this flask in incubator.
3. Transfer 10 mL wash medium into an empty 15 mL centrifuge tube. Incubate tube in 37°C
water bath
4. Quickly thaw cells in a 37°C water bath (~2 min) and transfer into the 15 mL centrifuge
tube containing the wash medium.
5. Centrifuge for 5 min at 500xg
6. Remove the tube from centrifuge and remove the wash medium by aspiration.
7. Gently resuspend the pellet in 5 mL supplemented Claycomb medium and add to the 10 mL
of medium already in the plate.
8. Replace the medium with 15 mL of fresh supplemented Claycomb medium 4 hours alter
(after cells have attached).
C. Culturing
1. Coat culture plates with gelatin/fibronectin for at least 1 hour at 37C. This can be done
overnight if more convenient. Be sure to agitate the plates in order to spread the solution
evenly.
a. 1 ml per well for a 6-well plate
b. 3 ml for a 100 cm plate or T75 flask
2. Remove the gelatin/fibronectin and add Complete Claycomb to the plates.
3. Thaw vial of HL-1 cells and pour into 9 ml Claycomb Wash Medium.
4. Count the cells.
5. Centrifuge the cells @200 xg for 10 min. Remove wash medium and resuspend in an
appropriate volume of Complete Claycomb Medium.
a. Final volume for each type of plate:
i. 2 ml/well for a 6-well dish
ii. 10 ml for a 100 mm plate
iii. 15 ml for a T75 flask
6. Add the cells to the plates and incubate at 37C.
7. Check the cells daily and replace the media every 2 days. Double the volume if leaving the
cells over the weekend.
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D. Subculturing
• For a 1:3 split
1. Remove media and rinse 1x with PBS.
a. 1 ml/well for a 6-well dish
b. 5 ml for a 100 mm plate or T75 flask
2. Add 0.05% trypsin/EDTA to the plate and incubate for 1 min at 37C.
a. 1 ml/well for a 6-well dish
b. 2 ml for a 100 mm plate
c. 3 ml for a T75 flask
3. Replace the trypsin/EDTA with fresh and incubate for 2 min at 37C.
4. Check to see if cells are dislodged. If not, rap plates on bench until completely floating;
may take 5-10 min.
5. Add Claycomb Wash to plate (volume equal to double the trypsin volume)
6. Transfer the cells to a conical tube and centrifuge at 500g for 5 min.
7. Cells are now ready for passaging or freezing.
Passaging: resuspend cells in Complete Claycomb and follow the culturing procedure.
Freezing: suspend the cells in ice cold freezing medium (1 x 106 cells/ml). Transfer to
cryovials (1 ml/vial), put in thawed freezing container, and put in ultracold freezer.
E. Freezing
One T75 flask/100 mm into one cryovial
1. Briefly rinse the plate with HL-1 culture with 5 mL of PBS warmed to 37°C. Remove via
aspiration.
2. Transfer 3 mL of 0.05% trypsin/EDTA into the plate.
3. Incubate the flask at 37°C for 1 minute
4. Remove the trypsin/EDTA from the flask and replace with 3 mL of fresh 0.05%
trypsin/EDTA. Incubate for 2 min.
5. Check to see if cells have dislodged. If not, rap plates on bench until completely floating;
may take 5-10 min.
6. Add 8 mL of Claycomb wash medium to the flask and transfer 6 mL into a 15 mL
centrifuge tube.
7. Rinse the empty plate with 8 mL wash medium and add the cells already in the 15 mL tube;
14 mL total volume
8. Centrifuge tube for 5 minutes at 500xg
9. Remove wash medium by aspiration.
10. Gently resuspend cells into a cryovial. Place the cryovial containing the cells into a Nalgene
freezing jar containing room temp isopropanol. Freeze at -80°C; transfer to liquid nitrogen
the next day
11. Immediately place the freezing jar in a -80°C freezer and freeze the cells at a rate of 1°C/minute.
12. 6 to 12 hours later, transfer the vial to a liquid nitrogen drawer.
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APPENDIX 2
C166 Cell Culture Procedures
Provided by ATCC
I. C166 MEDIA SOLUTIONS
Supplemented DMEM
DMEM
450mL
FBS
50 mL
Pen/Strep
5mL
Freezing Medium
Media 9.5 mL
DMSO 0.5 mL
II. C166 CELL CULTURE PROTOCOL
A. Subculturing
1. Remove and discard the culture medium.
2. Briefly rinse the cell layer with Dulbecco’s Phosphate Buffered Saline (PBS).
NOTE: This step removed all traces of serum that contains trypsin inhibitors.
3. Remove the PBS from the plate.
4. Add 2.0 mL of Trypsin- EDTA Solution to the plate.
5. Incubate cells in 37°C, 50% CO2 for 3-6 minutes; do not exceed 10 minutes
6. Once the cells are loose, add 8 mL of medium to the plate. Pipet cells and medium up and
down to mix.
7. Prepare the correct number of plates (label with initials, date, cell type, passage #) and add 9
mL of complete medium to 100 mm plate (For 6-wells: 1 mL per well)
8. Add 1 mL of cells to each plate (For 6-wells: 0.5 mL per well)
9. Incubate plates in a 37°C, 5% CO₂ incubator.
B. Freezing
1. Remove and discard culture medium.
2. Briefly rinse the cell layer with Dulbecco’s Phosphate Buffered Saline (PBS).
3. Remove the PBS from the plate.
4. Add 2.0 mL of Trypsin- EDTA Solution to the plate.
5. Incubate plates in a 37 °C, 5% CO₂ incubator for 3-6 minutes.

6.
7.
8.
9.
10.
11.
12.

*Note: After 3 minutes, check to see if the cells have let go of the plate (look at the plate
under the microscope). If the cells are still attached place back in the incubator for 2-3 more
minutes. DO NOT EXCEED 10 MINUTES.
Once the cells are loose, add 8 mL of medium to the plate. Pipet cells and medium up and
down to mix.
Add the entire content of the plate to a 15 mL centrifuge tube.
Centrifuge the tubes at 3000 rpm for 5 minutes.
Remove the medium from the tube, only leaving the pellet inside.
Add 1.5 mL of medium + DMSO to each tube. Pipet up and down to remove the pellet.
Remove all of the liquid from the tube and add it to a 2 mL tube.
Place all tube into the -80°C freezer overnight before placing them in the liquid nitrogen the
next day.
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V. C166 TRANSFECTION
1. Plate 0.5 mL cells in 1 mL on inserts the day before
a. Use Claycomb Media for C166’s in addition to HL-1’s
2. For each transfection sample, prepare oligomer-Lipofectamine 2000 complexes as follows:
a. 15 µL siRNA + 750 µL Opti-MEM
i. TWO FoxO1 siRNA tubes/6-well plate
1. 6 tubes/experiment
ii. ONE Control siRNA tubes/6-well plate
1. 3 tubes/experiment
b. 10 µL Lipofectamine + 750 µL Opti-MEM
i. 9 tubes/experiment
ii. Incubate at room tempertaure for 5 minutes
c. Mix two solutions together
i. Incubate at room temperature for 20 minutes
3. Remove medium from wells using the vacuum.
4. Rinse each well with PBS.
5. Add the oligomer-Lipofectamine complexes to each well containing cells and medium.
6. Mix gently by rocking back and forth.
7. Incubate cells at 37°C, 5% CO₂ incubator for 48 hours *Note: Change media after 4-6 hours
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APPENDIX 3
Western Blot Protocol
Provided by Dr. Laura Glasscock

Pouring Gel
1. Pour separating (running) gel (10%, denaturing):
- Prop cassette up with clips on a paper towel
- In a beaker, mix:
3.12 ml 40% acrylamide
3.12 ml 4x running buffer
6.25 ml dH20
- Immediately before you pour the gel, add:
41.26 ml 10% APS (catalyst)
6.25 ml TEMED (polymerizes acrylamide)
- Using a pipette, slowly pour gel in-between cassettes to spacer mark.
- Overlay gel with approx. 800 ml butanol
- Let gel polymerize.
- Dispose of butanol; use a piece of filter paper to remove residual butanol.
Stacking gel:
- In a beaker, mix:
0.624 ml acrylamide
1.55 ml 4x stacking buffer
4 ml dH20
37.5 ml 10% APS
12.5 ml TEMED
- Pipette onto top of running gel until you reach the top of the shorter plate.
- Place spacer in gel and let polymerize (approx. 15’)
Sample preparation:
1. Add sample buffer to your sample.
-Final Volume: 20 mL: 10 mL sample + 10mL 2x Sample Buffer
Running the gel:
1. Remove small clips from gel sides and remove tape.
2. Remove the spacer.
3. Using 1x running buffer (Laemlli), fill the space behind the gel to the top and the
bottom chamber about 1 inch.
4. Using a syringe, remove all bubbles.
5. Load samples into each well.
6. Connect lid and electrodes to the power source. Run under constant current.
- Set current to 15 mA for approx. 15 min.
- Turn current up to 30-35 mA
- Volts should be about 100.
8. When the dye front reaches the bottom, turn the power supply off and disconnect the
power supply from the gel.
9. Dispose of running buffer and open cassette to remove gel
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Western Blotting
Prepare blot for transfer: about 30’ before gel is through:
1. Cut nitrocellulose and submerge in MeOH in a small dish for about 60 sec.
2. Pour in Towbin buffer to completely submerge, plus extra, components.
- Let this equilibrate for approx. 20’ before assembling with gel.
1/2 x Towbin buffer for everything.
3. Remove gel from cassettes under buffer with your finger. Assemble cassette UNDER
BUFFER as follows: 2 sponges, 2 pieces. filter paper, nitrocellulose (line up marks,
orientation), gel (“gel side back”), 2 pieces. filter paper, 2 sponges
5. Load “sandwich” into transfer cassette then load into transfer chamber (gel side back).
7. Fill cassette with 1/2 x Towbin buffer to top of sponges (bellow screws). Fill transfer
chamber about 2 inches.
Transfer:
1. Transfer at 25 V, constant voltage for 1-2 hours 1 hour
- Current should be about 250-500
- Check every 20’ or so to see if over heating.
2. Turn power source off, disconnect, disassemble sandwich.
3. Use nitrocellulose in WB probing/detection steps.
Probing:
1. Place one nitrocellulose blot in each pipette tip lid or other small container.
2. Block with 3% milk in 1x TBS buffer, 30’, rocking.
3. Rinse with TBS.
4. Add primary antibody:
- Dilution: 1:1000
- Make in 1% milk/TBS
- Rock 3 hours-overnight
5. Rinse with TBS.
Wash 3x, 5’ each, with TBS while rocking.
6. Add secondary antibody:
- Anti-rabbit HRP-conjugated (SCBT) to enzyme for substrate
- Dilution: 1:10000
- Rock 1-3 hours or overnight
7. Rinse with TBS.
Wash 2x, 5’ each, with TBS while rocking.
Wash 1x with distilled water. Leave it in this until you do the ECL.
8. Detection: ECL
ECL detection:
1. Remove wash solution but leave blot in lid.
2. Prop one end of the lid up and add approx. 4 ml each ECL reagent to the bottom of the
lid (do not touch blot yet). Mix 2 reagents in lid gently.
3. Un-prop lid and cover blot. Let sit for 1 minute.
4. Remove blot with tweezers, shake gently over paper towel, place on saran wrap and
cover (no bubbles, wrinkles, etc.)
5. Place blot on imaging surface of Bio-Rad Gel-Doc EZ machine and image blot.
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